McKesson Earnings Call Transcripts
Fiscal Year 2026
-
Leadership transition is underway with the CFO retiring after reaffirming guidance and overseeing the MedSurg separation. Strong financial results continue, driven by growth in pharmaceutical distribution, Oncology, and technology solutions, with stable trends in generics and specialty. Strategic focus remains on high-growth platforms and disciplined capital allocation.
-
CFO Britt Vitalone reflected on consistent performance, specialty growth, and technology innovation, including AI and expanded services. Specialty revenues and MSO integrations are strong, while MedSurg prepares for separation. Operational efficiency and customer focus remain priorities.
-
Delivered record revenue and double-digit adjusted EPS growth, driven by Oncology, Biopharma Services, and North American distribution. Raised full-year EPS guidance, completed European exit, and advanced Medical-Surgical separation, with strong cash flow and continued investment in technology.
-
Focused on oncology, biopharma, and technology, the company has delivered strong financial growth and is executing a disciplined portfolio strategy, including the separation of its medical business. Expansion in oncology and specialty areas, robust capital allocation, and resilient pharmacy support underpin long-term growth targets.
-
Second quarter fiscal 2026 saw 10% revenue growth to $103B and 39% EPS growth, driven by strong performance in North American Pharmaceutical, Oncology and Multispecialty, and Prescription Technology Solutions. Full-year EPS guidance was raised, with robust cash flow and continued portfolio transformation.
-
Q1 revenue rose 23% to $97.8B and adjusted operating profit grew 9%, driven by strong specialty, oncology, and biopharma services. Fiscal 2026 EPS guidance was raised, with continued investment in automation, acquisitions, and shareholder returns supporting long-term growth.
Fiscal Year 2025
-
Strong Q2 results led to raised full-year guidance, with robust growth in oncology, vision, and RxTS platforms. Automation, AI, and platform expansion drive efficiency and margin gains, while the medical business separation and generics strategy support long-term value.
-
Business transformation and automation have driven margin expansion, with a focus on specialty drugs and operational efficiency. Oncology and vision remain key growth platforms, while stable pricing and a fixed fee model support profitability. Adjusted EPS guidance reflects strong performance.
-
The event outlined a sharpened focus on oncology, multispecialty, and biopharma services, with updated segment structures and strong financial guidance for fiscal 2026. Strategic investments in technology, automation, and targeted M&A are driving growth, while capital allocation remains disciplined to maximize shareholder value.
-
The conference highlighted ongoing regulatory uncertainty around the MFN executive order, a strategic separation of the medical segment to unlock value, and robust financial performance driven by oncology and biopharma services. The generic market remains stable, prior authorization volumes are rising, and capital deployment continues to prioritize growth and shareholder returns.
-
Fiscal 2025 saw record revenue and EPS growth, driven by strong U.S. Pharmaceutical and Prescription Technology Solutions performance, strategic acquisitions, and portfolio optimization. Fiscal 2026 guidance projects continued double-digit growth, with major investments in oncology and biopharma services.
-
Diversified supply chain limits tariff impact, while U.S. pharma and oncology platforms drive growth. Biosimilars and GLP-1s offer margin opportunities despite cost pressures. Med-Surg targets are supported by cost savings and strong alternate site positioning. Long-term EPS growth outlook remains robust.
-
Q3 saw 18% revenue and 16% adjusted operating profit growth, with strong performance in U.S. Pharmaceutical and Prescription Technology Solutions. FY25 guidance was raised, and the PRISM Vision acquisition is set to expand specialty services and drive future accretion.
-
The event highlighted a strong focus on oncology and biopharma platforms, robust financial performance, and disciplined capital allocation. Ongoing investments in technology, portfolio optimization, and provider network expansion are expected to drive continued growth and innovation.
-
Record Q2 revenue and profit growth driven by U.S. pharmaceutical and specialty products, with strong cash flow supporting increased share repurchases and strategic investments. Guidance for FY25 EPS was raised, reflecting confidence in oncology and biopharma platforms.
-
First quarter revenue grew 6% to $79.3B and adjusted EPS rose 8%, prompting a raised full-year EPS outlook. U.S. Pharmaceutical and oncology assets drove growth, while Medical-Surgical faced primary care softness and restructuring. Dividend and share repurchase authorizations were increased.
Fiscal Year 2024
-
Strong execution on growth strategies in oncology and biopharma services led to robust financial results, with significant investments in automation, AI, and cost realignment. Expansion of the oncology platform, biosimilar opportunities, and disciplined capital deployment underpin future growth and shareholder value.
-
Revenue and EPS guidance were raised following strong Q2 results, driven by growth in U.S. pharma, oncology, and biopharma platforms. Investments in automation, digital, and portfolio optimization continue, with robust capital returns and a focus on long-term shareholder value.
-
Acquisition of Florida Cancer Specialists' services expands oncology scale and data capabilities, while divestiture of Canadian retail assets sharpens strategic focus. U.S. pharma and RxTS segments show steady growth, with Optum as a major new customer and automation initiatives underway.